Risks of Endo`s opioid painkiller outweigh benefits: FDA panel

Published 9y ago

The benefits of Endo International Plc’s long-acting opioid painkiller no longer outweigh its risks, an independent panel to the U.S. Food and Drug Administration (FDA) concluded on Tuesday. More »